Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards

Executive Summary

Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.

You may also be interested in...



Medicaid Rebates To Increase $3.95bn With Revision For Line Extensions

CMS issues interim final rule to ensure there’s ‘no confusion’ that line extensions are now subject to higher Medicaid rebate requirements.

Abuse-Deterrent Formulations Exempt From Medicaid Rebates Under Bill

Comprehensive opioid addiction legislation is considered by House-Senate conference committee on July 6.

Medicaid Add-On Rebates For Line Extensions Remain A Judgment Call

Manufacturers must continue to use their discretion on which line extensions should be subject to inflation-based Medicaid rebates in lieu of guidance from CMS in its recent AMP final rule.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS119569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel